Intelligent Bio Solutions Highlights Continued Expansion with Strategic Partnership in Spain and Andorra
Intelligent Bio Solutions (INBS) has expanded its fingerprint drug testing presence in Spain and Andorra through a strategic partnership with Detecto, a division of MTB Distribuciones Tecnologicas SL. The collaboration targets the Spanish drug testing market, projected to reach $448 million by 2030.
Major clients including Metro Barcelona and a large Rio Tinto-based mine currently require 1,000 drug testing cartridges monthly. The system has gained acceptance due to its non-invasive nature, easy collection process, and reduced maintenance costs through yearly calibration.
Detecto is expanding its focus to include law enforcement, rehabilitation, and maritime sectors, while seeing growth opportunities in ports, mining, and transportation. The partnership aims to leverage both companies' strengths to expand fingerprint sweat-based drug testing across various sectors.
Intelligent Bio Solutions (INBS) ha ampliato la sua presenza nel mercato dei test antidroga con impronte digitali in Spagna e Andorra attraverso una partnership strategica con Detecto, una divisione di MTB Distribuciones Tecnologicas SL. La collaborazione mira al mercato spagnolo dei test antidroga, che si prevede raggiungerà 448 milioni di dollari entro il 2030.
Clienti importanti, tra cui Metro Barcelona e una grande miniera basata a Rio Tinto, richiedono attualmente 1.000 cartucce per test antidroga al mese. Il sistema ha guadagnato accettazione grazie alla sua natura non invasiva, al processo di raccolta semplice e ai costi di manutenzione ridotti grazie alla calibrazione annuale.
Detecto sta ampliando il suo focus per includere le forze dell'ordine, la riabilitazione e i settori marittimi, mentre vede opportunità di crescita nei porti, nelle miniere e nei trasporti. La partnership mira a sfruttare i punti di forza di entrambe le aziende per espandere i test antidroga basati sul sudore delle impronte digitali in vari settori.
Intelligent Bio Solutions (INBS) ha ampliado su presencia en el mercado de pruebas de drogas con huellas dactilares en España y Andorra a través de una asociación estratégica con Detecto, una división de MTB Distribuciones Tecnologicas SL. La colaboración tiene como objetivo el mercado español de pruebas de drogas, que se proyecta alcanzará 448 millones de dólares para 2030.
Clientes importantes, incluyendo Metro Barcelona y una gran mina basada en Rio Tinto, requieren actualmente 1.000 cartuchos de pruebas de drogas mensualmente. El sistema ha ganado aceptación debido a su naturaleza no invasiva, su proceso de recolección fácil y los costos de mantenimiento reducidos a través de la calibración anual.
Detecto está ampliando su enfoque para incluir a las fuerzas del orden, la rehabilitación y los sectores marítimos, mientras ve oportunidades de crecimiento en puertos, minería y transporte. La asociación busca aprovechar las fortalezas de ambas empresas para expandir las pruebas de drogas basadas en el sudor de las huellas dactilares en varios sectores.
Intelligent Bio Solutions (INBS)는 MTB Distribuciones Tecnologicas SL의 부서인 Detecto와의 전략적 파트너십을 통해 스페인과 안도라에서 지문 약물 검사 시장을 확장했습니다. 이번 협력은 2030년까지 4억 4,800만 달러에 이를 것으로 예상되는 스페인 약물 검사 시장을 목표로 하고 있습니다.
메트로 바르셀로나 및 리오 틴토 기반의 대규모 광산을 포함한 주요 고객들은 현재 매달 1,000개의 약물 검사 카트리지를 필요로 하고 있습니다. 이 시스템은 비침습적인 특성, 간편한 수집 과정, 연간 교정을 통한 유지 관리 비용 절감으로 인해 수용을 얻었습니다.
Detecto는 법 집행, 재활 및 해양 분야로 초점을 확대하고 있으며, 항구, 광업 및 운송에서 성장 기회를 보고 있습니다. 이 파트너십은 다양한 분야에서 지문 기반의 땀을 이용한 약물 검사를 확장하기 위해 두 회사의 강점을 활용하는 것을 목표로 하고 있습니다.
Intelligent Bio Solutions (INBS) a élargi sa présence dans le domaine des tests de drogue par empreinte digitale en Espagne et en Andorre grâce à un partenariat stratégique avec Detecto, une division de MTB Distribuciones Tecnologicas SL. La collaboration vise le marché espagnol des tests de drogue, qui devrait atteindre 448 millions de dollars d'ici 2030.
Des clients majeurs, y compris Metro Barcelona et une grande mine basée à Rio Tinto, nécessitent actuellement 1 000 cartouches de tests de drogue par mois. Le système a gagné en acceptation grâce à sa nature non invasive, à son processus de collecte facile et à des coûts de maintenance réduits grâce à une calibration annuelle.
Detecto élargit son champ d'action pour inclure les forces de l'ordre, la réhabilitation et les secteurs maritimes, tout en voyant des opportunités de croissance dans les ports, l'exploitation minière et le transport. Le partenariat vise à tirer parti des forces des deux entreprises pour développer les tests de drogue basés sur la sueur des empreintes digitales dans divers secteurs.
Intelligent Bio Solutions (INBS) hat seine Präsenz im Bereich der Fingerabdruck-Drogentests in Spanien und Andorra durch eine strategische Partnerschaft mit Detecto, einer Abteilung von MTB Distribuciones Tecnologicas SL, erweitert. Die Zusammenarbeit zielt auf den spanischen Drogentestmarkt ab, der voraussichtlich bis 2030 448 Millionen Dollar erreichen wird.
Wichtige Kunden, darunter Metro Barcelona und eine große Mine in Rio Tinto, benötigen derzeit monatlich 1.000 Drogentestkassetten. Das System hat aufgrund seiner nicht-invasiven Natur, des einfachen Sammelprozesses und der reduzierten Wartungskosten durch jährliche Kalibrierung Akzeptanz gefunden.
Detecto erweitert seinen Fokus auf die Bereiche Strafverfolgung, Rehabilitation und maritime Sektoren und sieht Wachstumschancen in Häfen, Bergbau und Transport. Die Partnerschaft zielt darauf ab, die Stärken beider Unternehmen zu nutzen, um den Fingerabdruck-basierten Schweiß-Drogentest in verschiedenen Sektoren auszubauen.
- Secured major clients requiring 1,000 cartridges monthly
- Targeting Spanish drug testing market worth $448M by 2030
- Expansion into new sectors (law enforcement, rehabilitation, maritime)
- Lower maintenance costs due to yearly calibration system
- None.
Insights
This partnership announcement represents a meaningful expansion for INBS's fingerprint drug testing technology in Spain and Andorra. The existing 1,000 monthly cartridge requirement from major clients like Metro Barcelona and a significant Spanish mining operation confirms real-world commercial traction and establishes a recurring revenue stream, albeit modest initially.
The Spanish drug testing market's projected growth to
INBS's differentiated value proposition is clear—non-invasive testing, simplified collection, worker acceptance, and reduced maintenance costs through yearly calibration. These advantages address specific pain points in workplace safety applications where traditional testing methods face resistance.
This expansion follows a typical medical technology commercialization strategy—partnering with established distributors to penetrate new geographic markets while focusing on specific high-value applications. The expansion into ports, mining, transportation, law enforcement and rehabilitation indicates a deliberate market segmentation approach, targeting sectors with stringent safety requirements and regulatory drivers.
INBS's expansion into Spain and Andorra addresses a critical need in workplace safety protocols, particularly in high-risk sectors. The adoption by Metro Barcelona and a major mining operation is especially noteworthy, as these environments present significant safety risks where impairment detection is essential.
The fingerprint sweat-based testing approach solves several persistent challenges in workplace drug screening programs. Traditional urine and blood testing methods face worker resistance, privacy concerns, and collection difficulties. Non-invasive fingerprint testing significantly reduces these barriers while maintaining detection efficacy.
The integration into existing security protocols at client sites suggests the technology complements rather than replaces current safety systems—an important consideration for adoption in risk-averse industrial environments where implementation friction can derail new technology deployment.
Annual calibration represents a substantial operational advantage over competing systems requiring more frequent maintenance. This reduces both direct maintenance costs and operational disruptions, a compelling proposition for continuous industrial operations like mining and transportation.
The expansion into maritime, ports, and additional transportation sectors aligns perfectly with European workplace safety regulations becoming increasingly stringent regarding substance impairment testing. These industries face particular pressure to implement more comprehensive safety protocols while maintaining operational efficiency.
INBS set to capitalize on growing Spanish Drug Testing Market, anticipated to reach
Major Spanish accounts currently require 1,000 drug testing cartridges per month
NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has expanded access to its fingerprint drug testing in Spain and Andorra through a strategic collaboration with Detecto, a division of Spanish distributor MTB Distribuciones Tecnologicas SL ("MTB").
MTB established Detecto following decades of experience in clinical distribution, recognizing the market's evolving needs and increasing demand for drug testing across various sectors. Detecto is now a leading provider of drug testing solutions throughout Spain and Andorra. INBS' partnership with Detecto aims to leverage the strengths of both companies and expand access to fingerprint sweat-based drug testing across various sectors, including workplace safety and transportation.
Detecto already supplies INBS' solution to major clients in these sectors, including transportation network, Metro Barcelona, and one of Spain's largest mines based out of Rio Tinto, where INBS’ solution is integrated into existing security protocols to enhance workplace safety. The testing volumes of these accounts currently require a supply of 1,000 cartridges per month to Detecto, reflecting the trust and confidence these accounts place in INBS' technology. The Company’s drug testing system has been well received among Detecto's clients due to its non-invasive nature, ease of collection, and increased acceptance among workers. Additionally, the system's yearly calibration reduces maintenance costs compared to other devices.
"Detecto's success in securing these large accounts in Spain is a strong indication of the wider adoption of our technology in the country," said Doug Heath, Vice President of Global Sales at Intelligent Bio Solutions. "These strategic partnerships are key to our expansion into the European market and the broader implementation of fingerprint drug screening across additional regions."
The Spanish drug testing market is anticipated to reach
About Detecto
Detecto was established as an independent business line within the company MTB Distribuciones Tecnologicas SL to provide the best possible service to professionals working in the prevention and treatment of addictive behaviors. Today, Detecto is a leading supplier in this sector in Spain, offering training and information to its clients on new drugs, technologies, and more. The Spanish labor market and the increasing emphasis on worker safety and well-being, particularly in high-risk sectors, is a key focus for Detecto which has achieved considerable success. Detecto provides consulting services to companies across Spain concerning substance abuse in the workplace, its safety implications, and prevention strategies. The company further provides advice to businesses on how to offer their employees an ethical, legal, and effective way to prevent the abuse of psychoactive substances. As part of this service, Detecto supplies cutting-edge technology to detect substance use in a way that is minimally invasive and highly effective.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.
For more information, visit: http://www.ibs.inc
Forward-Looking Statements:
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.'s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions' public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Company Contact:
Intelligent Bio Solutions Inc.
info@ibs.inc
LinkedIn | Twitter
Investor & Media Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
INBS@kcsa.com
Hyperlinks and website references in this release are provided for convenience only and do not incorporate the referenced content into this release.
1 Grand View Research. Spain Drug Testing Market Size & Outlook. Available at: https://www.grandviewresearch.com/horizon/outlook/drug-testing-market/spain
FAQ
What is the monthly cartridge demand for INBS drug testing in Spain?
What is the projected value of the Spanish drug testing market by 2030?
Who are the major clients using INBS drug testing in Spain?
What are the key advantages of INBS fingerprint drug testing system?
Which new sectors is INBS targeting through Detecto in Spain?
